ArticleOpen forum infectious diseases2020
Real-world Experience of Bezlotoxumab for Prevention of
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Adenosine deaminase co-immunization reverses age-associated immunosenescence by restoring germinal center T follicular helper cell function.bioRxiv : the preprint server for biology · 2026Article
- Heart Failure Incidence and Risk Factors in U.S. Adults Receiving Bezlotoxumab: A Large Database Analysis.Infectious disease reports · 2026Article
- Clinical Impact of Implementing a Specific Clinical Pathway for the Management of Clostridioides difficile Infection.Infectious diseases and therapy · 2026Article
- Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan.Antibiotics (Basel, Switzerland) · 2025Article
- Real-world use of bezlotoxumab to prevent recurrentTherapeutic advances in gastroenterology · 2025Article
- Management of Clostridioides difficile infection: an Italian Delphi consensus.The Journal of antimicrobial chemotherapy · 2024Article
- Bring it on again: antimicrobial stewardship in transplant infectious diseases: updates and new challenges.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Review
- Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Article
- Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment ofOpen forum infectious diseases · 2023Article
- The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.Infectious diseases and therapy · 2023Article
- The Role of Bezlotoxumab for the Prevention of RecurrentAntibiotics (Basel, Switzerland) · 2022Review
- The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review.Cureus · 2022Review
- Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Article
- Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice.Cancers · 2022Review
- ADS024, aFrontiers in microbiology · 2022Article
- Effectiveness of Bezlotoxumab for Prevention of RecurrentOpen forum infectious diseases · 2021Article
- Immune response againstTherapeutic advances in gastroenterology · 2021Review
- Fecal microbiota transplantation for recurrentTherapeutic advances in gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBezlotoxumab is approved for prevention of recurrence of
methodsRecords of patients receiving bezlotoxumab between April 2017 and December 2018 across 34 infusion centers in the United States were retrospectively reviewed. Recurrent CDI (rCDI), defined as diarrhea lasting ≥2 days resulting in treatment, was assessed 90 days postbezlotoxumab.
resultsThe study cohort included 200 patients (median age, 70 years; 66% female; median Charlson comorbidity index, 5), of whom 86% (n = 173) had prior CDI episodes and 79% (n = 158) had ≥2 risk factors for rCDI. SoC antibiotics included vancomycin (n = 137, 68%), fidaxomicin (n = 60, 30%), and metronidazole (n = 3, 2%). Median time from
conclusionsThis real-world multicenter study demonstrated successful prevention of rCDI with bezlotoxumab comparable to clinical trial results regardless of type of SoC and timing of infusion. Multiple prior CDI recurrences were associated with a higher risk of subsequent rCDI, supporting the use of bezlotoxumab earlier in the disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.